• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how weโ€™re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCEยฎ
    • BRINSUPRIยฎ
  • Responsibility

    Responsibility

    See how weโ€™re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCEยฎ
      BRINSUPRIยฎ
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Aug 27, 2018
    FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmedโ€™s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options
    Advisory committee supports surrogate endpoint of sputum culture conversion

    Read more

  • Aug 2, 2018
    Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update
    PDUFA (Prescription Drug User Fee Act) Action Date for ALIS (Amikacin Liposome Inhalation Suspension) Set for September 28, 2018

    Read more

  • Jul 26, 2018
    Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018

    Read more

  • Jun 15, 2018
    Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
    Meeting planned for August 7, 2018

    Read more

  • Jun 7, 2018
    Insmed to Present at Three June Conferences

    Read more

  • May 22, 2018
    Insmed Announces Presentations at the American Thoracic Society 2018 International Conference
    Data support the benefit of treating patients with a combination of ALIS (Amikacin Liposome Inhalation Suspension) and guideline-based therapy (GBT) for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC)

    Read more

  • May 17, 2018
    Insmed Appoints Leo Lee to its Board of Directors

    Read more

  • May 16, 2018
    Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC
    PDUFA Action Date Set for September 28, 2018

    Read more

  • May 2, 2018
    Insmed Reports First Quarter 2018 Financial Results and Provides Business Update
    Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension (ALIS) in NTM lung disease caused by MAC; anticipates priority review

    Read more

  • May 1, 2018
    Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference

    Read more

Show 5102550100 per page
  • «
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 78
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

ยฉ 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.